Secondary Progressive Multiple Sclerosis Clinical Trial
Official title:
Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (AMS04)
The primary goal of this study is to evaluate the effects of BAF312 (siponimod) on select immune and neuronal (nerve) cells by examining laboratory specimens (blood and/or spinal fluid) at multiple time points, prior to, and following the initiation of BAF312 or placebo treatment, in patients with Secondary Progressive Multiple Sclerosis (SPMS) who are enrolled in a clinical trial (NCT01665144) to evaluate the effectiveness and safety of BAF312.
This study is complementary to a multi-center, randomized, double-blind,parallel-group, placebo-controlled, variable treatment duration study comparing the efficacy and safety of BAF312 to placebo in patients with SPMS (NCT01665144). Investigators will explore both immunological and neuroprotective mechanisms of BAF312 (siponimod), a novel agent in the setting of a SPMS clinical trial. This study is part of a multi-center study, with the University of Michigan serving as the central site. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04239664 -
Acceptance Based Telephone Support When Transitioning to SPMS
|
N/A | |
| Active, not recruiting |
NCT04411641 -
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
|
Phase 3 | |
| Completed |
NCT02549703 -
Mitochondrial Dysfunction and Disease Progression
|
||
| Terminated |
NCT01416181 -
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
|
Phase 3 | |
| Withdrawn |
NCT01181089 -
Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03471338 -
Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme
|
N/A | |
| Withdrawn |
NCT05029609 -
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
|
Phase 1 | |
| Completed |
NCT02228213 -
Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis
|
Phase 2 | |
| Terminated |
NCT02296346 -
Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis
|
N/A | |
| Completed |
NCT00559702 -
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
|
Phase 1 | |
| Terminated |
NCT03283826 -
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT02253264 -
A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
|
Phase 1 | |
| Completed |
NCT01737372 -
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
|
N/A | |
| Completed |
NCT00257855 -
A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
|
Phase 2 | |
| Recruiting |
NCT06292923 -
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
|
Phase 2 | |
| Active, not recruiting |
NCT01228396 -
AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT03896217 -
Simvastatin in Secondary Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT02495766 -
Autologous Mesenchymal Stromal Cells for Multiple Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT00813969 -
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
|
Phase 1 | |
| Completed |
NCT01077466 -
Natalizumab Treatment of Progressive Multiple Sclerosis
|
Phase 2 |